Search
Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Webnewswire
Leading newswire service
Home
Business
Tech
Education
Interviews and Features
Others
Books
CSR
Environment
Entertainment
Health and Wellness
Finance
Hospitality
International
Lifestyle
Sports
Startup
Travel
Home
Tags
Eisai
Tag: Eisai
Business
Japan – Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
-
November 30, 2021
0
Business
Japan – Eisai Receives the ‘Most Liked!’ IR Award at The 2021 IR Award
-
November 18, 2021
0
Business
Japan – Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
-
November 13, 2021
0
Business
Japan – Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference
-
November 13, 2021
0
Business
Japan – Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease
-
November 9, 2021
0
Business
Japan – Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study
-
November 5, 2021
0
Uncategorized
Japan – Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
-
September 29, 2021
0
Uncategorized
Japan – Eisai to Join The Global Environmental Initiative “RE100”
-
September 15, 2021
0
Uncategorized
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
-
September 14, 2021
0
Uncategorized
Japan – Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
-
September 1, 2021
0
Uncategorized
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
-
July 30, 2021
0
Uncategorized
Japan – Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment
-
July 30, 2021
0
Uncategorized
Japan – Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
-
July 27, 2021
0
Uncategorized
Japan – Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
-
July 1, 2021
0
Uncategorized
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
-
June 24, 2021
0
Uncategorized
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
-
June 18, 2021
0
Uncategorized
Japan – Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
-
June 15, 2021
0
Uncategorized
Japan – Eisai Receives Special Prize at Platinum Career Award 2021
-
June 9, 2021
0
Uncategorized
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
-
June 1, 2021
0
Uncategorized
Japan – Eisai and National Cancer Center Commence Joint Research and Development Project
-
May 15, 2021
0
Uncategorized
Japan – Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
-
May 10, 2021
0
Uncategorized
Japan – Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease
-
May 10, 2021
0
Uncategorized
Japan – KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
-
May 10, 2021
0
Uncategorized
Japan – Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer
-
May 10, 2021
0
Uncategorized
Japan – Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
-
March 31, 2021
0
Uncategorized
Japan – Eisai Awarded The New Diversity Management Selection 100
-
March 22, 2021
0
1
2
Page 2 of 2
